48
Participants
Start Date
November 30, 2005
Primary Completion Date
February 28, 2006
Study Completion Date
February 28, 2006
Vaccine diluent buffer (Placebo)
0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
C. difficile toxoid vaccine (2 µg)
0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
C. difficile toxoid vaccine (10 µg)
0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
C. difficile toxoid vaccine (50 µg)
0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
Orlando Clinical Research Center, Orlando
University of Kentucky, Lexington
Lead Sponsor
Sanofi
INDUSTRY